Literature DB >> 18452396

Serotonin transporter gene polymorphisms and sertraline response in major depression patients.

Ozlem Dogan1, Nevzat Yuksel, Mehmet Ali Ergun, Akin Yilmaz, Mustafa N Ilhan, Hatice Ersin Karslioglu, Aysegul Koc, Adnan Menevse.   

Abstract

Major depression (MD) has a complex multifactorial etiology with genetic and environmental factors contributing to the disorder. As with all antidepressant treatments, there is variability in drug response due to heredity, generally focusing on genetic polymorphism of the drug-metabolizing transporter genes. The serotonin transporter (5-HTT) gene is a particularly important candidate for genetic involvement in MD disorders owing to its key role in the regulation of serotonergic transmission and is therefore considered to be an interesting candidate in the mechanism of antidepressant drugs. In this study, we have focused on the associations between genetic polymorphisms in two regions of the 5-HTT gene (5-HTTLPR and VNTR) related to sertraline responses. Our sample consisted of 64 unrelated Turkish subjects who strictly met DSM-IV and CGI scores. There was no significant difference between the frequency of the SS, LS, LL, 9/10, 10/10, 9/12, 10/12, and 12/12 genotypes and responses to sertraline. However, the number of patients can be increased and different drugs can be studied in order to find a specific pharmacogenetic relation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452396     DOI: 10.1089/gte.2007.0089

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  10 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 2.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 3.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

Review 4.  Antidepressant response and the serotonin transporter gene-linked polymorphic region.

Authors:  Matthew J Taylor; Srijan Sen; Zubin Bhagwagar
Journal:  Biol Psychiatry       Date:  2010-07-07       Impact factor: 13.382

Review 5.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

6.  Pharmacogenetics of antidepressants.

Authors:  Concetta Crisafulli; Chiara Fabbri; Stefano Porcelli; Antonio Drago; Edoardo Spina; Diana De Ronchi; Alessandro Serretti
Journal:  Front Pharmacol       Date:  2011-02-16       Impact factor: 5.810

7.  PharmGKB summary: sertraline pathway, pharmacokinetics.

Authors:  Rachel Huddart; J Kevin Hicks; Laura B Ramsey; Jeffrey R Strawn; D Max Smith; Margarita Bobonis Babilonia; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2020-02       Impact factor: 2.000

8.  Genetic Variations in the Serotonergic System Mediate a Combined, Weakened Response to SSRI Treatment: A Proposed Model

Authors:  Adam Pettitt
Journal:  eNeuro       Date:  2015-06-05

9.  The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder.

Authors:  Zhili Zou; Yulan Huang; Jinyu Wang; Wenjiao Min; Bo Zhou
Journal:  BMC Psychiatry       Date:  2020-07-28       Impact factor: 3.630

Review 10.  Systematic review and meta-analysis of serotonin transporter genotype and discontinuation from antidepressant treatment.

Authors:  Andrew A Crawford; Glyn Lewis; Sarah J Lewis; Marcus R Munafò
Journal:  Eur Neuropsychopharmacol       Date:  2012-12-20       Impact factor: 4.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.